LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Inicio・Lista de Acciones・Incyte Corp

Incyte Corp

Cerrado

SectorSanidad

98.39 -0.67

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

96.99

Máximo

99.05

Métricas clave
By Trading Economics
Ingresos	4.1M 303M
Ventas	-234M 1.3B
P/B Media del Sector	14.17 51.415
BPA	1.81
Margen de beneficios	23.834
Empleados	2,844
EBITDA	-47M 367M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+10.09% upside

Dividendos
By Dow Jones
Próximas Ganancias	28 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	993M 20B
Apertura anterior	99.06
Cierre anterior	98.39

Noticias sobre sentimiento de mercado

By Acuity

35%

65%

111 / 346 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

59.52 / 62.66 Soporte y Resistencia

Incyte Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 may 2026, 22:54 UTC

Ganancias

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 may 2026, 23:51 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 may 2026, 23:51 UTC

Charlas de Mercado

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 may 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 may 2026, 23:45 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

13 may 2026, 23:17 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 may 2026, 23:16 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 may 2026, 23:15 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 may 2026, 23:14 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 may 2026, 23:02 UTC

Charlas de Mercado

Ganancias

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 may 2026, 22:59 UTC

Charlas de Mercado

Ganancias

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 may 2026, 22:24 UTC

Ganancias

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 may 2026, 22:23 UTC

Ganancias

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 may 2026, 22:23 UTC

Ganancias

Xero FY International Revenue Growth 47%>XRO.AU

13 may 2026, 22:22 UTC

Ganancias

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 may 2026, 22:19 UTC

Ganancias

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 may 2026, 22:19 UTC

Ganancias

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 may 2026, 22:18 UTC

Ganancias

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 may 2026, 22:16 UTC

Ganancias

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 may 2026, 22:15 UTC

Ganancias

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 may 2026, 22:15 UTC

Ganancias

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 may 2026, 22:13 UTC

Ganancias

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 may 2026, 22:12 UTC

Ganancias

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 may 2026, 22:11 UTC

Ganancias

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 may 2026, 22:11 UTC

Ganancias

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 may 2026, 22:10 UTC

Ganancias

Xero Did Not Declare a Dividend>XRO.AU

13 may 2026, 22:10 UTC

Ganancias

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 may 2026, 22:09 UTC

Ganancias

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 may 2026, 22:00 UTC

Ganancias

Cisco to Shed Jobs for All-In AI Push -- Update

13 may 2026, 21:11 UTC

Ganancias

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Comparación entre iguales

Cambio de precio

Incyte Corp previsión

Precio Objetivo

By TipRanks

10.09% repunte

Estimación a 12 Meses

Media 109.13 USD 10.09%

Máximo 135 USD

Mínimo 75 USD

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Incyte Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

17 ratings

Comprar

Mantener

Vender

De acuerdo con 17 analistas que ofrecen calificaciones bursátiles a para Incyte Corp Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

59.52 / 62.66Soporte y Resistencia

Bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

111 / 346 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation